Delving into the Latest Updates on APC-8020 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine, Dendritic cell vaccine

Synonyms

Multiple myeloma vaccine, Myeloma vaccine, Mylovenge

+ [2]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [3]

Active Indication-

Inactive Indication

AmyloidosisMultiple Myeloma

Originator Organization

Kirin Holdings Co., Ltd.

Active Organization-

Inactive Organization

Kirin Holdings Co., Ltd.

Dendreon Corp.

National Cancer Institute

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Biological therapies, such as interferon-gamma and aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines made from a person's white blood cells may help the body build an effective immune response to kill cancer cells. Giving biological therapy together with vaccine therapy may kill more cancer cells.
PURPOSE: This randomized phase II trial is studying how well giving aldesleukin or interferon gamma together with vaccine therapy works in treating patients with multiple myeloma.

Start Date01 Aug 2001

Sponsor / Collaborator

Mayo Clinic

[+1]

100 Clinical Results associated with APC-8020

Login to view more data

100 Translational Medicine associated with APC-8020

Login to view more data

100 Patents (Medical) associated with APC-8020

Login to view more data

4

Literatures (Medical) associated with APC-8020

01 Nov 2015·Clinical advances in hematology & oncology : H&O

Immune therapy in multiple myeloma.

Review

Author: Luptakova, Katarina ; Avigan, David

Although the advent of biologic therapies has resulted in improved outcomes for patients with multiple myeloma (MM), patients ultimately develop progressively resistant disease. As such, novel approaches are needed. There has been a renewed focus on the development of therapies that would allow redirection of patients' own immune systems to target malignant myeloma cells. Compared with healthy individuals, patients with MM exhibit immune dysregulation and an impaired capacity to develop antitumor immunity. Tumor cells induce tolerance by exploiting native immune pathways responsible for preventing autoimmunity and maintaining immunologic equilibrium. In this review, we will discuss the development of potent humoral and cellular agents directed against myeloma antigens, including novel monoclonal antibodies, myeloma vaccines, and T-cell therapies. We will also discuss the development of immune checkpoint inhibitors and immunomodulatory agents that allow manipulation of the immunologic milieu and support a more robust native immune response. There is a growing interest in combining these 2 approaches-such as pairing antimyeloma vaccines with immune checkpoint blockade-to achieve maximum efficacy of immunotherapy.

01 Jul 2013·Clinical Cancer ResearchQ1 · MEDICINE

Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients

Q1 · MEDICINE

Article

Author: Anderson, Kenneth ; Weller, Edie ; Kufe, Donald ; Campigotto, Federico ; Rowe, Jacob ; Rosenblatt, Jacalyn ; Levine, James D. ; Held, Viki ; Katz, Tami ; Somaiya, Poorvi ; Yuan, Yan Emily ; Uhl, Lynne ; Richardson, Paul ; Avivi, Irit ; Tzachanis, Dimitrios ; Dey, Bimalangshu R. ; Mills, Heidi ; Avigan, David ; Laubach, Jacob ; Joyce, Robin ; Vasir, Baldev ; Bisharat, Lina ; Raje, Noopur ; Boussiotis, Vassiliki ; Munshi, Nikhil C.

AbstractPurpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease.Experimental Design: Twenty-four patients received serial vaccinations with dendritic cell/myeloma fusion cells following posttransplant hematopoietic recovery. A second cohort of 12 patients received a pretransplant vaccine followed by posttransplant vaccinations. Dendritic cells generated from adherent mononuclear cells cultured with granulocyte macrophage colony-stimulating factor, interleukin-4, and TNF-α were fused with autologous bone marrow–derived myeloma fusion cells using polyethylene glycol. Fusion cells were quantified by determining the percentage of cells that coexpress dendritic cell and myeloma fusion antigens.Results: The posttransplant period was associated with reduction in general measures of cellular immunity; however, an increase in CD4 and CD8+ myeloma-specific T cells was observed after ASCT that was significantly expanded following posttransplant vaccination. Seventy-eight percent of patients achieved a best response of complete response (CR)+very good partial response (VGPR) and 47% achieved a CR/near CR (nCR). Remarkably, 24% of patients who achieved a partial response following transplant were converted to CR/nCR after vaccination and at more than 3 months posttransplant, consistent with a vaccine-mediated effect on residual disease.Conclusions: The posttransplant period for patients with multiple myeloma provides a unique platform for cellular immunotherapy in which vaccination with dendritic cell/myeloma fusion fusions resulted in the marked expansion of myeloma-specific T cells and cytoreduction of minimal residual disease. Clin Cancer Res; 19(13); 3640–8. ©2013 AACR.

01 Aug 2009·Zhongguo shi yan xue ye xue za zhi

[Construction of eukaryotic expressing vector of multiple myeloma mucin-1 and its expression in COS-7 cells in vitro].

Article

Author: Mou, Hong ; Liu, Yue-Bo ; Liu, Kun ; Huang, Gui-Yun ; Zhang, You ; Yao, Jin ; Yang, Hong ; Luo, Yun-Jiao

In order to construct an eukaryotic expression vector for gene of multiple myeloma mucin1 (muc1-2vntr) gene and to express it in COS-7 cells in vitro, so to provide the basic material for further research of multiple myeloma DNA vaccine. muc1-2vntr coding gene was used as a research gene and a KOZAK sequence was inserted before the gene Hind III and XbaI restriction sites were inserted before and after the coding gene. Then the whole sequence was synthesized and inserted into pcDNA3.1/myc-his B vector, and the resulted recombinant vector was transformed into E.coil competent cells to get an engineering strain, the recombinant plasmid pcDNA3.1-2vntr/myc-his B identified by restriction analysis and DNA sequencing were transfected into COS-7 cells by liposome-mediated gene transfer method. Finally, fluorescent microscopy was used to assess GFP expression and Western blot analysis using muc1 monoclonal antibody was used to recognize vntr, confirming the expression of vntr. The results showed that the full length of synthesized muc1-2vntr gene, as expected, was 140 bp. Both restriction analysis and DNA sequencing demonstrated that pcDNA3.1-2vntr/myc-his B included the whole translation frame region and muc1-2vntr gene. Furthermore, the fluorescence microscopy proved that the recombinant plasmid had been successfully transfected into COS-7 cells. The expression of mucin-1 protein was observed both in the transfected cell and the cell supernatant by Western blot. It is concluded that the pcDNA3.1-2vntr/myc-his B has been successfully constructed and expressed in COS-7 cells in vitro, which provides the basic material for further researches of mucin-1 function and possible multiple myloma DNA vaccine.

100 Deals associated with APC-8020

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyloidosis	Phase 2	-	Kirin Holdings Co., Ltd.	-
Amyloidosis	Phase 2	-	Dendreon Corp.	-
Multiple Myeloma	Phase 2	-	Kirin Holdings Co., Ltd.	-
Multiple Myeloma	Phase 2	-	Dendreon Corp.	-
Multiple Myeloma	Phase 2	-	Kirin Holdings Co., Ltd.	-
Multiple Myeloma	Phase 2	-	Dendreon Corp.	-